Evidence map›Paper›PMID 25972545›Full record

ArticleJournal of virology2015

Respiratory Syncytial Virus Infection Upregulates NLRC5 and Major Histocompatibility Complex Class I Expression through RIG-I Induction in Airway Epithelial Cells.

Xuancheng Guo, Taixiang Liu, Hengfei Shi, Jingjing Wang, Ping Ji, Hongwei Wang, Yayi Hou, Ren Xiang Tan, Erguang Li

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 47 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. The Role of Innate Immunity in Pulmonary Infections.BioMed research international · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Xuancheng GuoState Key Laboratory of Pharmaceutical Biotechnology and School of Medicine, Nanjing University, Nanjing, Jiangsu, China Jiangsu Laboratory of Molecular Medicine, Nanjing University, Nanjing, Jiangsu, China.
Taixiang LiuJiangsu Laboratory of Molecular Medicine, Nanjing University, Nanjing, Jiangsu, China Jiangsu Province Blood Center, Nanjing, Jiangsu, China.
Hengfei ShiState Key Laboratory of Pharmaceutical Biotechnology and School of Medicine, Nanjing University, Nanjing, Jiangsu, China Jiangsu Laboratory of Molecular Medicine, Nanjing University, Nanjing, Jiangsu, China.
Jingjing WangState Key Laboratory of Pharmaceutical Biotechnology and School of Medicine, Nanjing University, Nanjing, Jiangsu, China College of Life Sciences, Nanjing University, Nanjing, Jiangsu, China.
Ping JiState Key Laboratory of Pharmaceutical Biotechnology and School of Medicine, Nanjing University, Nanjing, Jiangsu, China Jiangsu Province Blood Center, Nanjing, Jiangsu, China.
Hongwei WangJiangsu Laboratory of Molecular Medicine, Nanjing University, Nanjing, Jiangsu, China.
Yayi HouState Key Laboratory of Pharmaceutical Biotechnology and School of Medicine, Nanjing University, Nanjing, Jiangsu, China Jiangsu Laboratory of Molecular Medicine, Nanjing University, Nanjing, Jiangsu, China.
Ren Xiang TanState Key Laboratory of Pharmaceutical Biotechnology and School of Medicine, Nanjing University, Nanjing, Jiangsu, China College of Life Sciences, Nanjing University, Nanjing, Jiangsu, China.
Erguang LiState Key Laboratory of Pharmaceutical Biotechnology and School of Medicine, Nanjing University, Nanjing, Jiangsu, China Jiangsu Laboratory of Molecular Medicine, Nanjing University, Nanjing, Jiangsu, China erguang@nju.edu.cn.ORCID http://orcid.org/0000-0002-3065-1336
Nanjing University · CNJiangsu Province Blood Center · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

unlabelledRespiratory syncytial virus (RSV) is the leading cause of acute respiratory tract viral infection in infants, causing bronchiolitis and pneumonia. The host antiviral response to RSV acts via retinoic acid-inducible gene I (RIG-I). We show here that RSV infection upregulates major histocompatibility complex class I (MHC-I) expression through the induction of NLRC5, a NOD-like, CARD domain-containing intracellular protein that has recently been identified as a class I MHC transactivator (CITA). RSV infection of A549 cells promotes upregulation of NLRC5 via beta interferon (IFN-β) production, since the NLRC5-inducing activity in a conditioned medium from RSV-infected A549 cells was removed by antibody to IFN-β, but not by antibody to IFN-γ. RSV infection resulted in RIG-I upregulation and induction of NLRC5 and MHC-I. Suppression of RIG-I induction significantly blocked NLRC5, as well as MHC-I, upregulation and diminished IRF3 activation. Importantly, Vero cells deficient in interferon production still upregulated MHC-I following introduction of the RSV genome by infection or transfection, further supporting a key role for RIG-I. A model is therefore proposed in which the host upregulates MHC-I expression during RSV infection directly via the induction of RIG-I and NLRC5 expression. Since elevated expression of MHC-I molecules can sensitize host cells to T lymphocyte-mediated cytotoxicity or immunopathologic damage, the results have significant implications for the modification of immunity in RSV disease. IMPORTANCE: Human respiratory syncytial virus (RSV) is the leading cause of bronchiolitis and pneumonia in infants and young children worldwide. Infection early in life is linked to persistent wheezing and allergic asthma in later life, possibly related to upregulation of major histocompatibility class I (MHC-I) on the cell surface, which facilitates cytotoxic T cell activation and antiviral immunity. Here, we show that RSV infection of lung epithelial cells induces expression of RIG-I, resulting in induction of a class I MHC transactivator, NLRC5, and subsequent upregulation of MHC-I. Suppression of RIG-I induction blocked RSV-induced NLRC5 expression and MHC-I upregulation. Increased MHC-I expression may exacerbate the RSV disease condition due to immunopathologic damage, linking the innate immune response to RSV disease.

Indexed as

AnimalsChlorocebus aethiopsDEAD Box Protein 58DEAD-box RNA HelicasesEpithelial CellsHLA-A AntigensHLA-B AntigensHLA-C AntigensHumansIntracellular Signaling Peptides and ProteinsLungReceptors, ImmunologicRespiratory Syncytial Virus, HumanRespiratory Syncytial Virus InfectionsUp-RegulationVero CellsDEAD Box Protein 58DEAD-box RNA HelicasesHLA-A AntigensHLA-B AntigensHLA-C AntigensIntracellular Signaling Peptides and ProteinsNLRC5 protein, humanReceptors, ImmunologicRIGI protein, human

Identifiers

PMID25972545
PMCPMC4505675
OpenAlexW1564498973

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.